Many of our products/injections are widely used in physician offices as a weight loss tool to assist with increased energy and weight loss
The drug is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).
The synergistic activation of GIP and GLP-1 receptors has been recognized as a promising therapeutic approach in the treatment of T2D and obesity (17, 18)
We conclude that E2 directly controls both - and L cells to increase GLP-1 secretion, in addition to its effects on insulin and glucagon secretion, highlighting the potential beneficial role of the estrogenic pathway and, more particularly, of ER agonists to prevent type 2 diabetes
Goal: moderate weight loss (10 to 15% of body weight) If your target is 10 to 15% body weight reduction, you may not need to escalate beyond 4 to 8 mg
Over Dose Consuming more amount of tablets than the prescribed dose may lead to overdose